Evidence map›Paper›PMID 35422934›Full record

ArticleAmerican journal of translational research2022

Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment.

Chongguang Lin, Tao Fang, Jiayue Chen, Qianchen Li, Weiliang Yang, Cong Yao, Lina Wang, Yun Sun, Ziyao Cai, Jing Ping and 9 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chongguang LinDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Tao FangKey Laboratory of Real Time Tracing of Brain Circuit of Neurology and Psychiatry (RTBNP_Lab), Tianjin Medical University Affiliated Tianjin Fourth Center Hospital, The Fourth Central Hospital Affiliated to Nankai University, Tianjin Fourth Center Hospital Tianjin 300140, China.
Jiayue ChenKey Laboratory of Real Time Tracing of Brain Circuit of Neurology and Psychiatry (RTBNP_Lab), Tianjin Medical University Affiliated Tianjin Fourth Center Hospital, The Fourth Central Hospital Affiliated to Nankai University, Tianjin Fourth Center Hospital Tianjin 300140, China.
Qianchen LiDepartment of Pharmacology, First Hospital/First Clinical Medical College of Hebei Medical University Shijiazhuang 050000, Hebei, China.
Weiliang YangKey Laboratory of Psychiatric-Neuroimaging-Genetics and Comorbidity of Schizophrenia (PNGC_Lab), Tianjin Anding Hospital, Tianjin Mental Health Center Tianjin 300300, China.
Cong YaoKey Laboratory of Psychiatric-Neuroimaging-Genetics and Comorbidity of Schizophrenia (PNGC_Lab), Tianjin Anding Hospital, Tianjin Mental Health Center Tianjin 300300, China.
Lina WangKey Laboratory of Psychiatric-Neuroimaging-Genetics and Comorbidity of Schizophrenia (PNGC_Lab), Tianjin Anding Hospital, Tianjin Mental Health Center Tianjin 300300, China.
Yun SunKey Laboratory of Psychiatric-Neuroimaging-Genetics and Comorbidity of Schizophrenia (PNGC_Lab), Tianjin Anding Hospital, Tianjin Mental Health Center Tianjin 300300, China.
Ziyao CaiDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Jing PingDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Ce ChenDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Langlang ChengDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Jinjing ZhuDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Guangdong ChenDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Peiwei ShanDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Chunmian ChenDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Xiaodong LinDepartment of Psychiatry, Key Laboratory of Comorbidity, Wenzhou Seventh Peoples Hospital Wenzhou 325000, Zhejiang, China.
Hongjun TianKey Laboratory of Real Time Tracing of Brain Circuit of Neurology and Psychiatry (RTBNP_Lab), Tianjin Medical University Affiliated Tianjin Fourth Center Hospital, The Fourth Central Hospital Affiliated to Nankai University, Tianjin Fourth Center Hospital Tianjin 300140, China.
Chuanjun ZhuoKey Laboratory of Real Time Tracing of Brain Circuit of Neurology and Psychiatry (RTBNP_Lab), Tianjin Medical University Affiliated Tianjin Fourth Center Hospital, The Fourth Central Hospital Affiliated to Nankai University, Tianjin Fourth Center Hospital Tianjin 300140, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a study protocol designed to test the safety and efficacy of the 2019 coronavirus disease (COVID-19) vaccine in patients with major psychotic disease. A secondary objective is to investigate optional vaccination methods for these patients. In a self-experiment, a Chinese psychiatrist examined the safety and efficacy of the COVID-19 vaccine under clinical use of typical antipsychotic agents and sedatives (olanzapine, duloxetine, and diazepam). For patients with extremely drug-resistant conditions, the safety of the COVID-19 vaccine under electroconvulsive therapy was also investigated. The entire study process was recorded on high-definition video. This clinical study protocol is, to our knowledge, the first of its kind. Our findings will shed new light on the protection of patients with psychotic diseases from COVID-19 infection. The protocol was registered at Chinese clinical trial registry (www.chictr.org.cn, ChiCTR2100051297).

Indexed as

COVID-19 vaccinediazepamduloxetineelectroconvulsive therapyolanzapinepsychotic disease

Identifiers

PMID35422934
PMCPMC8991108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.